Related references
Note: Only part of the references are listed.Antidepressants and quality of life in patients with major depressive disorder - Systematic review and meta-analysis of double-blind, placebo-controlled RCTs
Teresa Wiesinger et al.
ACTA PSYCHIATRICA SCANDINAVICA (2023)
The Role of Psychological Interventions in the Maintenance Treatment of Depression
Elisabeth Schramm et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2022)
Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression A Systematic Review and Meta-analysis
Jonathan Henssler et al.
JAMA PSYCHIATRY (2022)
Dose effects of tricyclic antidepressants in the treatment of acute depression - A systematic review and meta-analysis of randomized trials
Christopher Baethge et al.
JOURNAL OF AFFECTIVE DISORDERS (2022)
Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas
Juan José Yepes-Nuñez et al.
Revista española de cardiología (English ed.) (2021)
Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder A Systematic Review and Meta-analysis
Jenny Guidi et al.
JAMA PSYCHIATRY (2021)
Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials
Lena Rink et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2021)
Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder
Takeshi Inoue et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2020)
In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis
C. Braun et al.
ACTA PSYCHIATRICA SCANDINAVICA (2020)
One (effect) size does not fit at all: Interpreting clinical significance and effect sizes in depression treatment trials
Fredrik Hieronymus et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial
Takeshi Inoue et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2018)
Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder
Akira Nishimura et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2018)
Long-Term Acute-Phase Treatment With Antidepressants, 8 Weeks and Beyond: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials
Jonathan Henssler et al.
JOURNAL OF CLINICAL PSYCHIATRY (2018)
Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence The CAST Randomized Clinical Trial
S. Susan Hedayati et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial
Jesse R. Fann et al.
JOURNAL OF HEAD TRAUMA REHABILITATION (2017)
Social functioning in patients with depressive and anxiety disorders
I. M. J. Saris et al.
ACTA PSYCHIATRICA SCANDINAVICA (2017)
The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Vanessa C. Evans et al.
CNS DRUGS (2016)
Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months
Sidney H. Kennedy et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder
Michael E. Thase et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2016)
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis
Andrea Cipriani et al.
LANCET (2016)
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder
Paula L. Jacobsen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
Jean-Philippe Boulenger et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
Angelo Sambunaris et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Escitalopram Treatment of Depression in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome A Randomized, Double-Blind, Placebo-Controlled Study
Jacqueline Hoare et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2014)
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
David Bakish et al.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2014)
A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder
Michael R. Liebowitz et al.
BMC PSYCHIATRY (2013)
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
Atul R. Mahableshwarkar et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
The Efficacy of Agomelatine in Elderly Patients With Recurrent Major Depressive Disorder: A Placebo-Controlled Study
Reinhard Heun et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
Stuart A. Montgomery et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Gregory M. Asnis et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder
Anita H. Clayton et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Efficacy and Safety of Desvenlafaxine 25 and 50 Mg/Day in a Randomized, Placebo-Controlled Study of Depressed Outpatients
Nakao Iwata et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2013)
Systematic Review of Blinding Assessment in Randomized Controlled Trials in Schizophrenia and Affective Disorders 2000-2010
Christopher Baethge et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2013)
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol
Tina Marie Myers Oakes et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2012)
A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder
Neven Henigsberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical
Paula J. Gaynor et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study
Paula J. Gaynor et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Symptomatic and Functional Improvement in Employed Depressed Patients A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo
Boadie W. Dunlop et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
10-year course of social adjustment in major depression
Toshi A. Furukawa et al.
INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY (2011)
Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes
Daniel Weintraub et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2010)
Trajectories of recovery of social and physical functioning in major depression, dysthymic disorder and double depression: A 3-year follow-up
Didi Rhebergen et al.
JOURNAL OF AFFECTIVE DISORDERS (2010)
Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder
Susan G. Kornstein et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
John Zajecka et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2010)
Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
Karen Hewett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder
K. Hewett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
K. Hewett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
Michael R. Liebowitz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Maintenance treatment for old-age depression preserves health-related quality of life: A randomized, controlled trial of paroxetine and interpersonal psychotherapy
Alexandre Y. Dombrovski et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2007)
A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure
Stephen S. Gottlieb et al.
AMERICAN HEART JOURNAL (2007)
Social functioning - Should it become an endpoint in trials of antidepressants?
P Bech
CNS DRUGS (2005)
An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression
LS Schneider et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Social Adaptation Self-evaluation Scale (SASS):: Psychometric analysis as outcome measure in the treatment of patients with major depression in the remission phase
P Bech et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE (2002)
Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo
JH Kocsis et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
The Work and Social Adjustment Scale: a simple measure of impairment in functioning
JC Mundt et al.
BRITISH JOURNAL OF PSYCHIATRY (2002)
Share Paper
